PMID- 31927749
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20221207
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
VI  - 68
IP  - 3
DP  - 2020 Jun
TI  - Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist 
      dulaglutide in patients with type 2 diabetes: a systematic review and 
      meta-analysis of 21 randomized controlled trials.
PG  - 508-517
LID - 10.1007/s12020-020-02193-9 [doi]
AB  - OBJECTIVES: To assess the efficacy and safety of once weekly glucagon-like 
      peptide-1 receptor agonist (GLP-1 RA) dulaglutide for the treatment of type 2 
      diabetes mellitus (T2DM). MATERIALS AND METHODS: We searched PubMed, Embase, and 
      Cochrane Library from inception to August 18, 2019. Revman5.3 and Stata13.0 
      software were used for meta-analysis. RESULTS: Twenty-one trials including 20,367 
      patients were analyzed. Compared with control group, hemoglobin A1c (HbA1c) in 
      0.75 mg dulaglutide group and 1.5 mg dulaglutide group were reduced by 0.29% and 
      0.55%, respectively. More patients treated with 0.75 mg dulaglutide [RR 1.24, 95% 
      CI (1.08, 1.42), p = 0.002] and 1.5 mg dulaglutide [RR 1.66, 95% CI (1.40, 1.99), 
      p < 0.00001] had reached the target of HbA1c 7.0%. In patients with T2DM, 0.75 mg 
      dulaglutide and 1.5 mg dulaglutide had a statistically higher adverse events 
      (AEs) incidence than control, whereas the risk of hypoglycaemia was lower in 
      0.75 mg dulaglutide group and 1.5 mg dulaglutide group than in control group. 
      CONCLUSIONS: Based on the current evidence, 0.75 and 1.5 mg dulaglutide are 
      associated with better glycemic control and lower rate of hypoglycemia in 
      patients with T2DM.
FAU - Qie, Suhui
AU  - Qie S
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, Shijiazhuang, 050051, Hebei Province, China.
FAU - Li, Xuejing
AU  - Li X
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, Shijiazhuang, 050051, Hebei Province, China.
FAU - Wang, Xianying
AU  - Wang X
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, Shijiazhuang, 050051, Hebei Province, China.
FAU - Liu, Yang
AU  - Liu Y
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, Shijiazhuang, 050051, Hebei Province, China.
FAU - Li, Jingxin
AU  - Li J
AD  - Department of Chinese pharmacy, Hebei Maternity Hospital, 27 Shifeng Road, Qiaoxi 
      District, Shijiazhuang, 050051, Hebei Province, China.
FAU - Liu, Guoqiang
AU  - Liu G
AUID- ORCID: 0000-0003-3838-716X
AD  - Department of Pharmacy, The Third Hospital of Hebei Medical University, 139 
      Ziqiang Road, Qiaoxi District, Shijiazhuang, 050051, Hebei Province, China. 
      liugq1223@sohu.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200111
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - WTT295HSY5 (dulaglutide)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Glucagon-Like Peptide-1 Receptor
MH  - Glucagon-Like Peptides/analogs & derivatives
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Immunoglobulin Fc Fragments
MH  - Randomized Controlled Trials as Topic
MH  - Recombinant Fusion Proteins
OTO - NOTNLM
OT  - Dulaglutide
OT  - Efficacy
OT  - Meta-analysis
OT  - Safety
OT  - Systematic review
OT  - Type 2 diabetes mellitus
EDAT- 2020/01/14 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/01/14 06:00
PHST- 2019/10/27 00:00 [received]
PHST- 2020/01/05 00:00 [accepted]
PHST- 2020/01/14 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/01/14 06:00 [entrez]
AID - 10.1007/s12020-020-02193-9 [pii]
AID - 10.1007/s12020-020-02193-9 [doi]
PST - ppublish
SO  - Endocrine. 2020 Jun;68(3):508-517. doi: 10.1007/s12020-020-02193-9. Epub 2020 Jan 
      11.